GLP-2 analog given twice a week for short bowel syndrome with intestinal failure. It has a favorable opinion in the EU and was rejected for now in the US.
Regulatory status
In clinical trials
Family
Long-acting GLP-2 analog
Scientific evidence
Moderate
Number of findings
1
Where it acts
Digestion and weight
Also known as
glepaglutide, ZP1848, Zeydovio
Regulatory status
FDA (US): Not approved: complete response letter (December 2024) for insufficient evidence; the FDA requested another trial.
EMA (EU): Not yet approved: positive CHMP opinion (September 2026, Zeydovio) for adults with short bowel syndrome; pending the European Commission's decision.
Dose
There is no established dose in humans. In the phase 3 EASE-1 trial, 10 mg subcutaneously twice a week for 24 weeks was used (Gastroenterology 2025).
Safety
Described as safe and well tolerated in the phase 3 trial; the publication's abstract does not detail adverse-effect rates. Only under the supervision of specialized intestinal failure units.
Effect by goal · level of evidence
Need for intravenous nutrition in short bowel
reducesModerateRCT (AA)in people
−5.1 L/week
EASE-1 trial (106 patients, 24 weeks): with 10 mg twice a week, intravenous support fell by 5.13 L/week vs 2.85 L/week with placebo; 14% were able to stop it completely (0% with placebo). The once-weekly regimen was not significant.
Activates the GLP-2 receptor in the intestine, which increases the surface area and absorptive capacity of the mucosa. This way the patient can absorb more fluids and nutrients and depend less on intravenous support.
What the evidence says
In people
Need for intravenous nutrition in short bowel syndrome. EASE-1 trial (106 patients, 24 weeks): with 10 mg twice a week, intravenous support fell by 5.13 L/week vs 2.85 L/week with placebo; 14% were able to stop it completely (0% with placebo). The once-weekly regimen was not significant. PubMed 39708985